```html

Zollinger‑Ellison Gastro‑Intestinal Bleeding

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (“gastrinomas”) arise in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of gastric acid, which can erode the lining of the stomach and duodenum. When this acid‑induced erosion leads to ulcers that break open, patients experience gastro‑intestinal (GI) bleeding. This guide focuses on the bleeding complication of ZES, a medical emergency that requires prompt recognition and treatment.

Who it affects: ZES can occur at any age, but most cases are diagnosed between 30 and 60 years. There is a slight male predominance (≈55 %). About 25 % of patients have multiple endocrine neoplasia type 1 (MEN 1), a hereditary condition that increases the risk of gastrinomas and other endocrine tumors.

Prevalence: Gastrinomas are rare, with an estimated incidence of 0.5–2 cases per million people per year. GI bleeding occurs in roughly 30‑40 % of ZES patients, most often because of peptic ulcer disease (PUD) that has become complicated.

Symptoms

Bleeding from a ZES‑related ulcer may present suddenly or develop gradually. Common symptoms, grouped by system, include:

Gastro‑intestinal Bleeding

• Hematemesis: Bright‑red or coffee‑ground vomiting, indicating upper GI bleeding.
• Melena: Black, tarry stools caused by digested blood.
• Occult blood: Positive fecal occult blood test without visible discoloration.

Ulcer‑Related Discomfort

• Epigastric pain: Burning or gnawing pain, often worse after meals or when the stomach is empty.
• Refractory ulcer disease: Ulcers that fail to heal after 8‑12 weeks of standard proton‑pump inhibitor (PPI) therapy.

Systemic Effects of Hyperacidity

• Diarrhea (often fatty) due to acid inactivation of pancreatic enzymes.
• Weight loss and malnutrition.
• Fatigue from chronic anemia.

MEN 1‑Related Features (if present)

• Hyperparathyroidism (high calcium, kidney stones).
• Pituitary adenomas (headaches, visual changes).

Causes and Risk Factors

Understanding the root cause helps clinicians target therapy and patients recognize personal risk.

Primary Cause

• Gastrinomas: Neuroendocrine tumors that secrete gastrin independent of normal feedback mechanisms. Approximately 80‑90 % arise in the duodenum, 10‑20 % in the pancreas, and a few are ectopic.

Risk Factors

• Genetic predisposition: MEN 1 mutation (≈25 % of ZES cases).
• Family history: First‑degree relatives with ZES or MEN 1.
• Age & sex: Peak incidence 30‑60 years; slight male predominance.
• Chronic Helicobacter pylori infection: While not a direct cause of gastrinomas, H. pylori can aggravate acid‑related ulcer disease and increase bleeding risk.

Diagnosis

Diagnosing ZES with GI bleeding requires a stepwise approach that confirms hypergastrinemia, identifies the tumor, and evaluates the source of bleeding.

Laboratory Tests

• Fasting serum gastrin level: > 1,000 pg/mL (normal < 100 pg/mL) is highly suggestive, especially when the gastric pH is < 2.
• Secretin stimulation test: A rise in gastrin > 200 pg/mL after intravenous secretin is diagnostic for gastrinoma.
• Complete blood count (CBC): Detects anemia from chronic blood loss.
• Serum calcium & PTH: Screen for MEN 1‑related hyperparathyroidism.

Imaging Studies

• Contrast‑enhanced CT or MRI of the abdomen: First‑line for tumor localization; detects masses as small as 1 cm.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Highly sensitive for neuroendocrine tumors, especially when CT/MRI is negative.
• EUS (Endoscopic ultrasound): Useful for small duodenal lesions and for fine‑needle aspiration (FNA) biopsy.

Endoscopic Evaluation

• Upper endoscopy (EGD): Direct visualization of ulcers, assessment of stigmata of recent hemorrhage, and ability to apply therapeutic measures (clips, coagulation, injection).
• Capsule endoscopy or double‑balloon enteroscopy: Considered if bleeding source is suspected distal to the duodenum.

Pathology

If tissue is obtained (EUS‑FNA or surgical specimen), histology confirms a neuroendocrine tumor, typically positive for chromogranin A and synaptophysin.

Treatment Options

Therapy aims to control acid hypersecretion, stop the bleeding, and eradicate or control the tumor.

Acid Suppression (First‑line)

• High‑dose proton‑pump inhibitors (PPIs): Ombudsen 80 mg IV bolus followed by 8 mg/h infusion, then oral 40–80 mg twice daily. PPIs raise gastric pH > 4, allowing ulcer healing and reducing re‑bleeding risk.
• H2‑receptor antagonists: Occasionally added if PPIs are insufficient, but PPIs remain the cornerstone.

Management of Acute Bleeding

• Endoscopic hemostasis: Injection of epinephrine, thermal coagulation, or hemostatic clips.
• Trans‑arterial embolization (TAE): For refractory bleeding when endoscopy fails.
• Surgical intervention: Limited to uncontrolled hemorrhage, perforation, or when the tumor is resectable.

Tumor‑Directed Therapy

• Surgical resection: Preferred for localized gastrinomas; can be curative in 40‑60 % of cases.
• Somatostatin analogues (e.g., octreotide, lanreotide): Inhibit gastrin release and control symptoms; especially useful for metastatic disease.
• Targeted therapy: Everolimus or sunitinib for advanced neuroendocrine tumors.
• Peptide‑receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE for tumors expressing somatostatin receptors.

Adjunctive Measures

• H. pylori eradication: Triple therapy (clarithromycin, amoxicillin, PPI) if infection is present.
• Iron, folate, and vitamin B12 supplementation: To treat anemia.
• Blood product transfusion: RBCs for hemodynamic instability or severe anemia (Hb < 7 g/dL).

Lifestyle & Dietary Modifications

• Avoid NSAIDs, aspirin, and other ulcer‑causing drugs.
• Limit alcohol and caffeine, which stimulate gastric acid.
• Eat small, frequent meals; avoid large, fatty meals that increase gastric secretions.

Living with Zollinger‑Ellison Gastro‑Intestinal Bleeding

Long‑term management focuses on preventing ulcer recurrence, monitoring for tumor progression, and maintaining overall health.

Medication Adherence

• Take PPIs exactly as prescribed—usually twice daily—even if symptoms improve.
• Keep a medication diary; set reminders on phone or pillbox.

Regular Follow‑up

• Endoscopy every 1–2 years to assess ulcer healing.
• Imaging (CT/MRI or Ga‑68 DOTATATE PET) every 6–12 months for tumor surveillance.
• Labs: fasting gastrin, CBC, calcium, and renal function at each visit.

Nutrition

• High‑protein, low‑fat diet; incorporate calcium‑rich foods if hyperparathyroidism is absent.
• Consider a registered dietitian experienced in acid‑related disorders.

Support & Education

• Join patient groups (e.g., Neuroendocrine Tumor Research Foundation).
• Maintain a symptom journal: note any melena, hematemesis, new abdominal pain, or changes in stool color.

Prevention

While the underlying gastrinoma cannot be prevented, steps can reduce the risk of bleeding and complications:

• Never use NSAIDs or aspirin without a protective PPI.
• Screen and treat H. pylori infection early.
• Adhere to high‑dose PPI therapy as recommended by your gastroenterologist.
• Avoid smoking—it impairs ulcer healing.
• Maintain regular follow‑up to catch tumor growth before it leads to larger ulcers.

Complications

If left untreated or inadequately managed, ZES‑related GI bleeding can lead to serious outcomes:

• Severe anemia requiring repeated transfusions.
• Perforated ulcer → peritonitis, sepsis.
• Obstruction: Duodenal scarring causing gastric outlet obstruction.
• Metastatic disease: Up to 60 % of gastrinomas metastasize, most often to the liver, complicating both bleeding control and tumor therapy.
• Electrolyte disturbances: Chronic diarrhea can cause hypokalemia, metabolic alkalosis.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Institutes of Health (NIH), American College of Gastroenterology, World Health Organization (WHO), Cleveland Clinic, Journal of Clinical Endocrinology & Metabolism, Annals of Surgery.

```